IN2014MN01781A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01781A IN2014MN01781A IN1781MUN2014A IN2014MN01781A IN 2014MN01781 A IN2014MN01781 A IN 2014MN01781A IN 1781MUN2014 A IN1781MUN2014 A IN 1781MUN2014A IN 2014MN01781 A IN2014MN01781 A IN 2014MN01781A
- Authority
- IN
- India
- Prior art keywords
- cdim
- binding proteins
- cells
- well
- diagnostic assays
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 abstract 4
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 4
- 108091008324 binding proteins Proteins 0.000 abstract 4
- 238000003556 assay Methods 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000025171 antigen binding proteins Human genes 0.000 abstract 1
- 108091000831 antigen binding proteins Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 230000000779 depleting effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261633330P | 2012-02-08 | 2012-02-08 | |
| PCT/US2013/025430 WO2013120012A2 (en) | 2012-02-08 | 2013-02-08 | Cdim binding proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01781A true IN2014MN01781A (OSRAM) | 2015-07-03 |
Family
ID=48045015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1781MUN2014 IN2014MN01781A (OSRAM) | 2012-02-08 | 2013-02-08 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9409976B2 (OSRAM) |
| EP (1) | EP2812356B1 (OSRAM) |
| JP (1) | JP6335796B2 (OSRAM) |
| KR (1) | KR102102111B1 (OSRAM) |
| CN (1) | CN104254544B (OSRAM) |
| AU (1) | AU2013200903B2 (OSRAM) |
| BR (1) | BR112014019459B1 (OSRAM) |
| CA (1) | CA2863714C (OSRAM) |
| DK (1) | DK2812356T3 (OSRAM) |
| ES (1) | ES2735289T3 (OSRAM) |
| IN (1) | IN2014MN01781A (OSRAM) |
| MX (1) | MX363819B (OSRAM) |
| TW (1) | TWI606064B (OSRAM) |
| WO (1) | WO2013120012A2 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3041862B1 (en) | 2013-09-05 | 2020-05-06 | IGM Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| KR20240042192A (ko) | 2013-12-17 | 2024-04-01 | 크링 바이오테라퓨틱스 비.브이. | 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법 |
| CN105992772A (zh) | 2014-02-10 | 2016-10-05 | Igm生命科学股份有限公司 | IgA多特异性结合分子 |
| AU2015240595B2 (en) | 2014-04-03 | 2020-02-27 | Igm Biosciences, Inc. | Modified J-chain |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| CA2978324A1 (en) | 2015-03-04 | 2016-09-09 | Igm Biosciences, Inc. | Cd20 binding molecules and uses thereof |
| CA2980751A1 (en) | 2015-03-25 | 2016-09-29 | Stephen F. Carroll | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| HK1245675A1 (zh) | 2015-04-17 | 2018-08-31 | Igm Biosciences, Inc. | 多价人免疫缺陷病毒抗原结合分子及其用途 |
| SI3355913T1 (sl) | 2015-09-30 | 2025-01-31 | Igm Biosciences, Inc. | Vezalne molekule z modificirano j-verigo |
| ES2819870T3 (es) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Moléculas de unión con cadena J modificada |
| PT3455257T (pt) | 2016-05-09 | 2021-12-06 | Igm Biosciences Inc | Anticorpos anti-pd-l1 |
| JP6851391B2 (ja) * | 2016-08-15 | 2021-03-31 | ノバルティス アーゲー | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| CA3221995C (en) | 2017-02-08 | 2024-05-28 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| WO2018187702A2 (en) | 2017-04-07 | 2018-10-11 | Igm Biosciences A/S | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
| PT3749346T (pt) | 2018-02-08 | 2024-09-05 | Dragonfly Therapeutics Inc | Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d |
| KR20200118824A (ko) | 2018-02-08 | 2020-10-16 | 드래곤플라이 쎄라퓨틱스, 인크. | 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법 |
| CA3091424A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| CA3091144A1 (en) | 2018-03-01 | 2019-09-06 | Igm Biosciences, Inc. | Igm fc and j-chain mutations that affect igm serum half-life |
| CA3108646A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| AU2019318083A1 (en) | 2018-08-08 | 2021-02-25 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| BR112021009373A2 (pt) * | 2018-11-16 | 2021-08-17 | Memorial Sloan Kettering Cancer Center | anticorpos para mucina-16 e métodos de uso dos mesmos |
| WO2021030688A1 (en) | 2019-08-15 | 2021-02-18 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| CN114181318B (zh) * | 2021-11-08 | 2023-08-01 | 四川大学 | 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US5246692A (en) | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5099069A (en) | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
| US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US6312691B1 (en) | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| US6962979B1 (en) | 1995-03-14 | 2005-11-08 | Cohesion Technologies, Inc. | Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6680335B2 (en) | 1998-09-28 | 2004-01-20 | Sugen, Inc. | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds |
| JP2003509428A (ja) | 1999-09-17 | 2003-03-11 | アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー | 治療薬としてのピラゾロピリミジン |
| US20020028178A1 (en) | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| EP1485075A4 (en) * | 2002-02-20 | 2006-04-26 | Dyax Corp | MHC-PEPTIDE COMPLEX BINDING LIGANDS |
| US7485297B2 (en) * | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
| JP2007513072A (ja) * | 2003-11-05 | 2007-05-24 | パリンゲン インコーポレーテッド | Ｃｄｉｍ結合抗体における増強されたｂ細胞細胞傷害性 |
| US20120237441A9 (en) * | 2003-11-05 | 2012-09-20 | Bhat Neelima M | Enhanced b cell cytotoxicity of cdim binding antibody |
| CA2586285A1 (en) * | 2004-11-05 | 2006-05-18 | Palingen, Inc. | Antibody induced cell membrane wounding |
| US7988971B2 (en) * | 2005-03-14 | 2011-08-02 | The United States Of America As Represented By The Department Of Health And Human Services | Human monoclonal antibodies against Hendra and Nipah viruses |
| AU2006292132A1 (en) * | 2005-09-19 | 2007-03-29 | Palingen, Inc. | Treatment of B cell diseases using anti-germline antibody binding agents |
| GT200800034A (es) * | 2007-04-02 | 2010-03-16 | Anticuerpos anti-ige |
-
2013
- 2013-02-08 IN IN1781MUN2014 patent/IN2014MN01781A/en unknown
- 2013-02-08 JP JP2014556751A patent/JP6335796B2/ja active Active
- 2013-02-08 TW TW102105337A patent/TWI606064B/zh active
- 2013-02-08 KR KR1020147025110A patent/KR102102111B1/ko active Active
- 2013-02-08 BR BR112014019459-9A patent/BR112014019459B1/pt active IP Right Grant
- 2013-02-08 US US13/763,398 patent/US9409976B2/en active Active
- 2013-02-08 MX MX2014009628A patent/MX363819B/es active IP Right Grant
- 2013-02-08 ES ES13713588T patent/ES2735289T3/es active Active
- 2013-02-08 WO PCT/US2013/025430 patent/WO2013120012A2/en not_active Ceased
- 2013-02-08 AU AU2013200903A patent/AU2013200903B2/en active Active
- 2013-02-08 DK DK13713588.5T patent/DK2812356T3/da active
- 2013-02-08 CN CN201380008515.XA patent/CN104254544B/zh active Active
- 2013-02-08 CA CA2863714A patent/CA2863714C/en active Active
- 2013-02-08 EP EP13713588.5A patent/EP2812356B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104254544B (zh) | 2017-04-26 |
| CA2863714C (en) | 2022-07-05 |
| MX363819B (es) | 2019-04-03 |
| JP2015511817A (ja) | 2015-04-23 |
| HK1205136A1 (en) | 2015-12-11 |
| EP2812356A2 (en) | 2014-12-17 |
| BR112014019459A8 (pt) | 2023-01-10 |
| KR20150001728A (ko) | 2015-01-06 |
| JP6335796B2 (ja) | 2018-06-06 |
| BR112014019459A2 (pt) | 2017-06-27 |
| US20140044739A1 (en) | 2014-02-13 |
| DK2812356T3 (da) | 2019-07-08 |
| AU2013200903B2 (en) | 2015-05-14 |
| TWI606064B (zh) | 2017-11-21 |
| ES2735289T3 (es) | 2019-12-17 |
| KR102102111B1 (ko) | 2020-04-20 |
| WO2013120012A3 (en) | 2013-11-07 |
| MX2014009628A (es) | 2015-03-19 |
| WO2013120012A2 (en) | 2013-08-15 |
| US9409976B2 (en) | 2016-08-09 |
| BR112014019459B1 (pt) | 2023-04-18 |
| CN104254544A (zh) | 2014-12-31 |
| TW201345921A (zh) | 2013-11-16 |
| CA2863714A1 (en) | 2013-08-15 |
| EP2812356B1 (en) | 2019-03-27 |
| AU2013200903A1 (en) | 2013-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01781A (OSRAM) | ||
| PH12019500441A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| MX349096B (es) | Anticuerpos anti-pd-l1 y sus usos. | |
| PH12018500640A1 (en) | Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi) | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
| PH12017501583B1 (en) | Novel proteins specific for cd137 | |
| MY177970A (en) | Bcma (cd269/tnfrsf17) -binding proteins | |
| BR112013019975A2 (pt) | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" | |
| BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
| IN2014CN03936A (OSRAM) | ||
| UA107706C2 (uk) | Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань | |
| PH12015500084A1 (en) | Rspo3 binding agents and uses thereof | |
| MY156286A (en) | Human il-23 antigen binding proteins | |
| MX2014000555A (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| IN2014CN04645A (OSRAM) | ||
| EP4477270A3 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| NZ701370A (en) | Il-6 binding molecules | |
| EA201370155A1 (ru) | Композиция и способ лечения рака | |
| BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos | |
| WO2013040547A3 (en) | Compounds and methods of immunization with tumor antigens | |
| TN2013000265A1 (en) | Anti-cd38 antibodies |